The acquisition of Vega Therapeutics represents a significant capital deployment and triggers a complex post-merger integration.
Filing excerpt
On July 6, 2026, Incyte Corporation (the “Company”) issued a press release announcing it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC (“Vega Therapeutics”).
What this signalsFilings often name leadership changes, deals and spending plans.
sec-8kcapexIncreaseGet every 8-K signal for Incyte and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/7b59cd6f-1984-46d9-a7f6-0d6d605638c3 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.
{
"signal_id": "7b59cd6f-1984-46d9-a7f6-0d6d605638c3",
"signal_type": "sec-8k",
"signal_subtype": "capexIncrease",
"detected_at": "2026-07-07T07:07:58.425+00:00",
"company": {
"name": "Incyte",
"domain": "incyte.com"
},
"data": {
"detail": "The acquisition of Vega Therapeutics represents a significant capital deployment and triggers a complex post-merger integration. This creates immediate needs for consolidating IT systems, aligning financial and HR platforms, and integrating R&D pipelines.",
"metrics": {
"timeframe": "immediate",
"dollar_context": "Acquisition of Vega Therapeutics"
},
"summary": "Incyte completes acquisition of Vega Therapeutics on July 6, 2026, signaling major strategic investment.",
"excerpts": "On July 6, 2026, Incyte Corporation (the “Company”) issued a press release announcing it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC (“Vega Therapeutics”).",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000048/incy-20260706.htm",
"filing_date": "2026-07-06",
"filing_year": 2026,
"fiscal_year_end": "07/06",
"sales_relevance": "Budget available",
"signal_category": "financial"
}
}
curl https://signals.autobound.ai/v1/signals/7b59cd6f-1984-46d9-a7f6-0d6d605638c3 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.